尽管持续亏损，但 Cardiol Therapeutics 的股价在收益略高于预期后上涨。 Cardiol Therapeutics' stock rose after earnings slightly beat expectations, despite ongoing losses.

Cardiol Therapeutics 报告的收益略高于预期，每股收益为 0.07 美元，而预期为 0.08 美元，导致其股价上涨至 0.97 美元。 Cardiol Therapeutics reported earnings that slightly beat expectations, with an EPS of ($0.07) compared to the expected ($0.08), causing its stock to rise to $0.97. 该公司专门从事心脏病治疗,目前正在第二阶段研究中测试其主导产品卡迪奥尔克斯。 The company specializes in heart disease therapies and is currently testing its lead product, CardiolRx, in a Phase II study. 心脏病治疗药品的市场上限为8 011万美元,“Buy”共识评级,平均目标价格为8.40美元。 Cardiol Therapeutics has a market cap of $80.11 million, a "Buy" consensus rating, and an average target price of $8.40.